<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Brakke&#x54A8;&#x8BE2;&#x7F51;&#x7AD9;</provider_name><provider_url>https://brakkeconsulting.com/zh</provider_url><title>News from Brakke Consulting</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="aunhZP3tD3"&gt;&lt;a href="https://brakkeconsulting.com/zh/22105/"&gt;2002&#x5E74;11&#x6708;27&#x65E5;&#x52A8;&#x7269;&#x5065;&#x5EB7;&#x65B0;&#x95FB;&#x4E0E;&#x7B80;&#x62A5;&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://brakkeconsulting.com/zh/22105/embed/#?secret=aunhZP3tD3" width="600" height="338" title="&#x300A;2002&#x5E74;11&#x6708;27&#x65E5;&#x52A8;&#x7269;&#x5065;&#x5EB7;&#x65B0;&#x95FB;&#x4E0E;&#x7B80;&#x8BAF;&#x300B;&#x2014;&#x2014;&#x5E03;&#x62C9;&#x514B;&#x54A8;&#x8BE2;&#x516C;&#x53F8;&#x7F51;&#x7AD9;" data-secret="aunhZP3tD3" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
//# sourceURL=https://brakkeconsulting.com/wp-includes/js/wp-embed.min.js
/* ]]&gt; */
&lt;/script&gt;</html><description>****************************************************************** Brakke Consulting&rsquo;s Animal Health News &amp; Notes for November 27, 2002 Copyright &copy; Brakke Consulting, Inc. ****************************************************************** Happy Thanksgiving.&nbsp;&nbsp; The newsletter is being broadcast this week on Wednesday rather than Friday due to the Thanksgiving holiday in the US.&nbsp; We hope everyone in the US enjoys their holiday.&nbsp; ****************************************************************** GET READY! Brakke Consulting&rsquo;s 2002 US Flea Control and Heartworm Markets will be available the first week of December, immediately after the US Thanksgiving holiday.&nbsp; This year&rsquo;s report will include an all-new survey of 250 dog and cat owners, as well as a new veterinarian survey.&nbsp; Product sales and trends for the veterinary products, as well as an overview of the trends in OTC sales, will also be included in the report. The report will be available until December 20, 2002 at an early-order price of $3,500.&nbsp; Studies ordered after the Christmas holiday will be priced at $4,000. For more information, call 972-243-4033 or email Dr. Lynn Fondon at lfondon@brakkeconsulting.com. ******************************************************************** COMPANY NEWS RELEASES &gt; IDEXX Laboratories, Inc. announced it has been informed verbally by the FDA that the FDA expects to provide further comments to the Company regarding its application for approval of nitazoxanide.&nbsp; As a result the Company anticipates an additional delay in the introduction of nitazoxanide. Nitazoxanide is a product for the treatment of equine protozoal myeloencephalitisView Full Post;</description></oembed>
